|Day's Range||0.2500 - 0.2500|
Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis. The QIAstat-Dx Gastrointestinal Panel delivered high performance compared to other, existing multiplex tests in this study which evaluated 385 patient samples at university hospital laboratories across Europe. Multiple pathogens were identified in nearly one-third of the patient samples that tested positive.
Rome, L6, based Investment company Bank of Italy (Current Portfolio) buys Qiagen NV, sells Ferrari NV during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Bank of Italy. Continue reading...
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After QIAGEN N.V.'s (NYSE:QGEN) earnings announcement in March 2019, analysts seem fairly confident, as a 19% increase...
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.